Purchase Order 75N91018P00476
Award Date
8/31/18
Potential Completion Date
8/30/19
Potential Value
$205K
Federal Agency
National Cancer Institute
Awardee
Lentigen Technology, Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
North Potomac, MD 20878, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lentigen Technology, Inc. for the manufacture of a good manufacturing practice (GMP) lot of a lentiviral vector encoding a CD19/CD22 targeting bispecific chimeric antigen receptor (CD19/CD22 BiCAR) gene for clinical use. The contract has a ceiling value of $322,000.00 and a completion date of August 7, 2017. The contract was awarded on August 8, 2016 and was not set aside...
This firm-fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Expression Manufacturing LLC, a for-profit limited liability company, to provide 250 ml of concentrated lentiviral vector and conduct stability testing. The contract, valued at $648,968.00, has an ultimate completion date of August 31, 2029. This sole-source procurement was originally...
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI) awarded a purchase order contract valued at one hundred twenty thousand six hundred dollars ($120,600) to Vector Biomed Inc. The contract is to obtain preclinical grade lentiviral vectors in support of NCI's Pediatric Oncology Branch investigational new drug enabling studies and demonstration of clinical-grade vector production feasibility. Services include receipt confirmation...
This firm fixed-price contract for $803,500.00 was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to Vector Biomed Inc. for the production and stability testing of clinical grade lentiviral vector. The services include manufacturing a minimum of 50mg of GMP/clinical grade transfer plasmid and 400ml of concentrated, GMP grade lentiviral vector, as well as performing stability testing...
This is a $4,696,754.00 cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for GD2 CAR T MANUFACTURING services, with a period of performance through September 29, 2024. As a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, Leidos Biomedical Research provides comprehensive biomedical research and facilities support services, including...
This federal contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to The New York Structural Biology Center, Inc., a non-profit organization, to provide services generating high resolution X-ray crystal structures of the extracellular domains of chimeric antigen receptor (CAR) proteins and other immunologically relevant surface receptors and co-receptors, as well as their interactions with tumor antigens. The contract is...
This is a delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $1,247,433.00 cost-plus-fixed-fee contract is for the administration of a GD2 CAR-T cell therapy clinical trial site and cell distribution logistics. The contract has an ultimate completion date of September 27, 2025. There is no set-aside designation indicated. Leidos Biomedical...
This is a firm-fixed-price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to the prime contractor Aldevron, L.L.C., a for-profit limited liability company that manufactures biologics. The contract is for the production and purification of custom DNA plasmids, specifically 600 mg of pM766 gp160 V1, 40 mg of pSW M766 gp120 V1, and 600 mg of SIV p57 Gag custom plasmids, to support ongoing research...
This firm-fixed price purchase order was awarded by the National Institutes of Health (NIH) Clinical Center, a civilian agency under the U.S. Department of Health and Human Services, to Sirion Biotech GmbH, a foreign-owned for-profit organization. The $21,966.56 contract provides LENTIBOOST formulated, Good Manufacturing Practice (GMP)-grade lentiviral products and other viral vector reagents from Sirion Biotech's facilities in Germany. These specialized reagents support gene therapy research...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a $243,100.71 firm fixed price purchase order to Childrens Hospital Medical Center (dba Children's Home Healthcare), a non-profit hospital located in Cincinnati, Ohio. The contract is for the production and biosafety testing of a current Good Manufacturing Practices (cGMP)-compliant transient gammaretroviral vector to be used in NCI clinical trials. The contract period of...